1. PRMT5/WDR77 Enhances the Proliferation of Squamous Cell Carcinoma via the ΔNp63α-p21 Axis.
- Author
-
Liang, Heng, Fisher, Matthew L., Wu, Caizhi, Ballon, Carlos, Sun, Xueqin, and Mills, Alea A.
- Subjects
- *
SQUAMOUS cell carcinoma , *ARGININE , *FLOW cytometry , *PROTEIN kinase inhibitors , *GENOMICS , *RESEARCH funding , *HEAD & neck cancer , *CELL proliferation , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *REVERSE transcriptase polymerase chain reaction , *METHYLTRANSFERASES , *CELL culture , *IMMUNOHISTOCHEMISTRY , *WESTERN immunoblotting , *GENE expression profiling , *DATA analysis software , *SEQUENCE analysis - Abstract
Simple Summary: Protein arginine methyltransferase 5 (PRMT5) is known to be oncogenic in many cancers, including squamous cell carcinoma (SCC). Our analyses of multiple public databases revealed that PRMT5 overexpression correlates with poor survival in SCC patients and is essential to the survival of SCC cell lines. This study focused on understanding how PRMT5 and its binding partner, WDR77 (WD repeat domain 77), regulate SCC cell growth, particularly through the p63 ΔNp63α isoform, a key factor in SCC. Furthermore, PRMT5 depletion inhibited SCC proliferation by inducing cell cycle arrest in the G1 phase. Additionally, we showed that PRMT5 and WDR77 stabilized ΔNp63α protein expression, which in turn inhibited p21 (cyclin-dependent kinase inhibitor 1). These findings provide new insights into the potential of targeting PRMT5 as a therapeutic strategy for SCC. Protein arginine methyltransferase 5 (PRMT5) is a critical oncogenic factor in various cancers, and its inhibition has shown promise in suppressing tumor growth. However, the role of PRMT5 in squamous cell carcinoma (SCC) remains largely unexplored. In this study, we analyzed SCC patient data from The Cancer Genome Atlas (TCGA) and the Cancer Dependency Map (DepMap) to investigate the relationship between PRMT5 and SCC proliferation. We employed competition-based cell proliferation assays, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assays, flow cytometry, and in vivo mouse modeling to examine the regulatory roles of PRMT5 and its binding partner WDR77 (WD repeat domain 77). We identified downstream targets, including the p63 isoform ΔNp63α and the cyclin-dependent kinase inhibitor p21, through single-cell RNA-seq, RT-qPCR, and Western blot analyses. Our findings demonstrate that upregulation of PRMT5 and WDR77 correlates with the poor survival of head and neck squamous cell carcinoma (HNSCC) patients. PRMT5/WDR77 regulates the HNSCC-specific transcriptome and facilitates SCC proliferation by promoting cell cycle progression. The PRMT5 and WDR77 stabilize the ΔNp63α Protein, which in turn, inhibits p21. Moreover, depletion of PRMT5 and WDR77 repress SCC in vivo. This study reveals for the first time that PRMT5 and WDR77 synergize to promote SCC proliferation via the ΔNp63α-p21 axis, highlighting a novel therapeutic target for SCC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF